Cephalexin Dosing for Uncomplicated UTI in a 66-Year-Old Female
Prescribe cephalexin 500 mg orally twice daily for 7 days for this uncomplicated urinary tract infection. This twice-daily regimen achieves equivalent clinical and microbiological cure rates to the traditional four-times-daily dosing while improving adherence and reducing cost. 1, 2, 3
FDA-Approved Dosing and Evidence Base
The FDA label authorizes cephalexin 500 mg every 12 hours for uncomplicated cystitis in patients over 15 years of age, with a recommended duration of 7–14 days. 1
A 2025 retrospective cohort of 214 ED patients with UTI found no statistically significant difference in treatment failure between twice-daily (18.7%) and four-times-daily (15.0%) cephalexin dosing (P = 0.465). For uncomplicated UTI specifically, failure rates were 14.9% versus 8.1% (P = 0.197). 2
A 2023 multicenter study of 261 women with uncomplicated UTI demonstrated that cephalexin 500 mg twice daily achieved a 12.7% treatment failure rate versus 17% with four-times-daily dosing (P = 0.343), with no difference in adverse events. 3
Why Twice-Daily Dosing Is Preferred Over Four-Times-Daily
Twice-daily dosing improves adherence by reducing pill burden from 28 doses to 14 doses over a 7-day course, a critical factor in outpatient therapy. 2, 3
Cephalexin achieves peak serum levels of approximately 18 mcg/mL one hour after a 500 mg dose and maintains measurable levels for 6 hours, with over 90% excreted unchanged in urine within 8 hours, producing peak urinary concentrations of approximately 2200 mcg/mL. 1
The 12-hour dosing interval is pharmacokinetically sound because cephalexin's urinary concentrations remain well above the MIC for common uropathogens (E. coli, Klebsiella pneumoniae, Proteus mirabilis) throughout the dosing interval. 1, 3
Treatment Duration: 7 Days Is Standard
The FDA label specifies 7–14 days for uncomplicated cystitis, and clinical practice favors 7 days for straightforward cases in non-pregnant women without complicating factors. 1
A 1994 randomized trial comparing single-dose fosfomycin to 5-day cephalexin 500 mg four times daily showed 91% clinical cure at 5 days and 81% sustained eradication at 1 month with the 5-day cephalexin regimen. 4 While this supports shorter courses, current FDA guidance and clinical practice endorse 7 days to ensure adequate eradication.
Extending beyond 7 days (to 10–14 days) is reserved for complicated UTI, delayed clinical response, or when upper-tract involvement cannot be excluded. 1
Cephalexin's Position in UTI Treatment Guidelines
The 2011 IDSA/ESMID guidelines list β-lactams (including cephalexin) as alternative rather than first-line agents for uncomplicated UTI, recommending nitrofurantoin, trimethoprim-sulfamethoxazole (if local resistance <20%), or fosfomycin as preferred options. 5
Oral β-lactams achieve approximately 89% clinical cure and 82% microbiological eradication, which is modestly inferior to first-line agents (nitrofurantoin: 93% clinical cure, 88% eradication; TMP-SMX: 93% clinical cure, 94% eradication). 5, 6
Cephalexin should be reserved for patients who cannot use first-line agents due to allergy, intolerance, or documented resistance. 5, 6
Microbiological Coverage and Susceptibility
Cephalexin is active against E. coli (the causative pathogen in 75–95% of uncomplicated cystitis), Klebsiella pneumoniae, and Proteus mirabilis when susceptible to cefazolin. 1, 2, 3
A 2023 pediatric study found 85.3% of lower UTI isolates susceptible to cephalexin, supporting its use when susceptibility is confirmed or highly probable. 7
Cephalexin has no activity against Pseudomonas spp., Acinetobacter, or Enterobacter spp., and methicillin-resistant staphylococci and enterococci are resistant. 1
Obtain a urine culture before initiating therapy if the patient has atypical symptoms, recent antibiotic exposure, recurrent UTI, or risk factors for resistant organisms; otherwise, empiric therapy is acceptable for straightforward uncomplicated cystitis. 5, 6
When to Avoid Cephalexin
Do not use cephalexin for suspected pyelonephritis or upper-tract infection because oral β-lactams have insufficient tissue penetration and higher failure rates compared with fluoroquinolones or parenteral agents. 6, 8
Do not use cephalexin when local E. coli resistance to first-generation cephalosporins exceeds 20% or when the patient has had recent β-lactam exposure (within 3 months), as resistance risk is markedly increased. 6
Avoid cephalexin in patients with documented penicillin allergy due to potential cross-reactivity (approximately 10% in IgE-mediated reactions). 6
Monitoring and Follow-Up
Reassess the patient at 72 hours if symptoms do not improve; persistent dysuria, frequency, or fever should prompt urine culture and consideration of alternative therapy. 5, 6
If symptoms recur within 2–4 weeks after completing therapy, obtain a urine culture and switch to a different antibiotic class (e.g., nitrofurantoin, TMP-SMX, or a fluoroquinolone if susceptible) for a full 7-day course. 5, 6
Routine post-treatment urine culture is not required for asymptomatic patients who have completed therapy successfully. 6
Practical Prescribing Summary
Prescribe: Cephalexin 500 mg orally twice daily for 7 days. 1, 2, 3
Counsel the patient to complete the full 7-day course even if symptoms resolve earlier, as premature discontinuation increases relapse risk. 1
Advise the patient to return if symptoms persist beyond 3 days or recur within 2 weeks, as this indicates possible treatment failure or resistant organism. 5, 6
Cephalexin may be taken without regard to meals because it is acid-stable and rapidly absorbed. 1